Alkaloid compound from davidia involucrata baill with anti-ev71 virus activity and preparation and application thereof
By isolating novel alkaloid compounds with anti-EV71 virus activity from the branches and leaves of Acer buergerianum, the problem of limited therapeutic effects of existing anti-EV71 virus drugs has been solved, providing candidate compounds for the development of highly effective and low-toxicity anti-EV71 drugs, which are suitable for the preparation and application of various drug formulations.
Patent Information
- Application Number
- CN202411927320.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-25
- Publication Date
- 2025-10-21
- Estimated Expiration
- 2044-12-25
AI Technical Summary
Existing anti-EV71 drugs, such as ribavirin, have limited efficacy and may cause liver damage with long-term use. There is a lack of specific, highly effective, and low-toxicity anti-EV71 drugs.
Four novel alkaloid compounds, including compounds 1–4, were isolated from the branches and leaves of Daphniphyllum calycinum. In particular, compounds 3 and 4 showed significant anti-EV71 virus activity, with EC50 values of 2.826 μg/mL and 3.783 μg/mL, respectively, which were superior to the EC50 of ribavirin (65.770 μg/mL).
Candidate compounds with good anti-EV71 virus activity are provided for the development of new anti-EV71 drugs. They are suitable for the preparation of anti-EV71 lead compounds and drugs, and can be used to prepare various dosage forms such as tablets, granules, capsules, pellets, sustained-release preparations, oral liquids, powders and injections for oral or parenteral administration.